Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients

Inclusion Criteria: * type 2 diabetes mellitus (T2DM) patients presenting with stable angina and a clinical indication for cardiac catheterization * T2DM patients with non ST elevation myocardial infarction (NSTEMI) or unstable angina referred for cardiac catheterization * Demonstration of coronary lesion(s) with non-significant fractional flow reserve (FFR) values (\>0.80), for which revascularisation is deferred * Agreement to practice an acceptable method of birth control for women of childbearing potential * Signed patient informed consent Exclusion Criteria: * Age \< 18 years old * T2DM patients presenting with ST elevation myocardial infarction (STEMI) * Pregnancy or breastfeeding * Body mass index ≥45 kg/m2 * Creatinine clearance ≤45 ml/min/1.73 m2 (as calculated by Modification of Diet in Renal Disease Study (MDRD ) formula for estimated Glomerular filtration rate (GFR)) * Indication of liver disease, defined by serum levels of alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 x upper limit of normal during screening or run-in phase * Uncontrolled hyperglycemia with glucose \>240 mg/dL after an overnight fast * Stroke, or transient ischemic attack at presentation and up to 2 months prior to informed consent * Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake * Any uncontrolled endocrine disorder except type 2 diabetes * Treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent * Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at time of screening leading to unstable body weight * Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years * Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells * Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption * Planned cardiac surgery or angioplasty within 3 months * Any clinical condition that would jeopardize patient safety while participating in this clinical trial * Life expectancy \< 3 years